Blue Jet Healthcare Limited held the groundbreaking ceremony for its new manufacturing facility at Industrial Park Rambilli Cluster Phase II, Anakapalli District, Andhra Pradesh on February 28, 2026. The ceremony was attended by Hon'ble Minister for IT, Electronics & Communications and HRD, Shri Nara Lokesh, along with senior officials of the Government of Andhra Pradesh, industry partners, customers, and investors.

Board-Approved Investment and Development Plans

The company's Board of Directors has approved Phase 1 of the project with a substantial investment commitment. The facility represents a strategic expansion initiative with significant long-term development potential.

Manufacturing Focus and Capabilities

The Vizag facility will concentrate on producing complex pharmaceutical intermediates and active pharmaceutical ingredients (APIs). This strategic focus aims to strengthen Blue Jet Healthcare's capabilities as a global supplier to pharmaceutical innovators. The project is designed to enhance the company's manufacturing platform to meet evolving pharmaceutical supply-chain requirements.

At full scale, the project is expected to generate high-skilled direct employment opportunities and contribute significantly to the development of the regional industrial ecosystem.

Management Commentary

Mr. Shiven Arora, Managing Director, emphasized the milestone's importance in the company's expansion strategy: "Phase 1 marks an important milestone in our long-term expansion strategy. We appreciate the clarity and responsiveness extended by the Government of Andhra Pradesh, which provided the confidence to invest at scale. Our objective is to develop a globally benchmarked manufacturing platform aligned with evolving pharmaceutical supply-chain requirements."

Mr. Akshay Arora, Executive Chairman, highlighted the company's growth trajectory: "Founded in 1968, Blue Jet Healthcare has grown with a strong focus on governance and long-term partnerships. The Vizag project represents a disciplined expansion aligned with global demand and the Company's multi-decade growth plans."

Strategic Alignment

The project aligns with Andhra Pradesh's industrial development objectives and supports India's broader agenda of strengthening advanced manufacturing and supply-chain resilience. Blue Jet Healthcare, established in 1968, operates as a manufacturer of specialty chemicals and pharmaceutical intermediates serving global pharmaceutical companies, maintaining focus on quality, compliance, and governance-led growth.

Blue Jet Healthcare Limited has announced the groundbreaking ceremony for its new manufacturing facility in Andhra Pradesh, marking a significant milestone in the company's expansion strategy. The ceremony is scheduled for February 28, 2026, representing the company's commitment to strengthening its manufacturing capabilities.

Facility Details and Location

The new manufacturing facility will be established at Industrial Park Rambilli Cluster Phase II, Anakapalli District, Andhra Pradesh. This strategic location is expected to enhance the company's operational reach and manufacturing capacity.

Strategic Growth Initiative

The announcement follows the company's earlier intimation dated July 31, 2025, indicating that this expansion has been part of a planned growth strategy. The new facility is positioned to address growing market demands and strengthen the company's overall infrastructure capabilities.

Company's Existing Manufacturing Network

Blue Jet Healthcare currently operates multiple manufacturing units across Maharashtra, including facilities in Shahad, Ambernath, and Mahad. The addition of the Andhra Pradesh facility will expand the company's geographical manufacturing presence and operational capacity.

Corporate Communication

The announcement was made through an official communication to stock exchanges on February 19, 2026, signed by Sweta Poddar, Company Secretary & Compliance Officer. The company has informed both BSE Limited and National Stock Exchange of India Limited about this significant development as part of its regulatory compliance obligations.